

Sansure Biotech secures \$77M led by Lilly Asia

03 January 2018 | News

The company, which focuses on molecular diagnosis and genetic testing techniques, also saw Junhe Capital participate in its latest funding round.



Hunan Province-based biotechnology firm Sansure Biotech has raised \$77 million from a group of investors led by Lilly Asia Ventures and HighLight Capital in a strategic financing round.

The company, which focuses on molecular diagnosis and genetic testing techniques, also saw Junhe Capital participate in its latest funding round.

Sansure provides innovative molecular diagnosis and genetic testing kits and tools to diagnostic labs and researchers.

It makes nucleic acid extraction kits, real time polymerase chain reaction (PCR) diagnostic and research kits and fluorescence systems. Sansure claims to be the second-largest China company in its market niche.

Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.